PRRT

You have access
Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms
Najeff Waseem, Carina Mari Aparici and Pamela L. Kunz

Journal of Nuclear Medicine July 1, 2019, 60 (7) 882-891; DOI: https://doi.org/10.2967/jnumed.118.217851
You have access
SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework
Rudolf A. Werner, Lilja B. Solnes, Mehrbod S. Javadi, Alexander Weich, Michael A. Gorin, Kenneth J. Pienta, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe and Constantin Lapa

Journal of Nuclear Medicine July 1, 2018, 59 (7) 1085-1091; DOI: https://doi.org/10.2967/jnumed.117.206631
You have access
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, M. Konijnenberg, B.L. Boen L.R. Kam, Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning and Dik J. Kwekkeboom

Journal of Nuclear Medicine March 1, 2018, 59 (3) 452-458; DOI: https://doi.org/10.2967/jnumed.117.189712
You have access
Dose Mapping After Endoradiotherapy with ¹⁷⁷Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
Heribert Hänscheid, Constantin Lapa, Andreas K. Buck, Michael Lassmann and Rudolf A. Werner

Journal of Nuclear Medicine January 1, 2018, 59 (1) 75-81; DOI: https://doi.org/10.2967/jnumed.117.193706
You have access
Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
Clément Morgat, Gaétan MacGrogan, Véronique Brouste, Valérie Vélasco, Nicolas Sévenet, Hervé Bonnefoi, Philippe Fernandez, Marc Debled and Elif Hindié

Journal of Nuclear Medicine September 1, 2017, 58 (9) 1401-1407; DOI: https://doi.org/10.2967/jnumed.116.188011
You have access
Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
Rachel Levine and Eric P. Krenning

Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 3S-9S; DOI: https://doi.org/10.2967/jnumed.116.186502
You have access
Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
Uta Eberlein, Marta Cremonesi and Michael Lassmann

Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 97S-103S; DOI: https://doi.org/10.2967/jnumed.116.186841
You have access
Upregulation of Key Molecules for Targeted Imaging and Therapy
Vincent F. Taelman, Piotr Radojewski, Nicolas Marincek, Anat Ben-Shlomo, Andrea Grotzky, Cristina I. Olariu, Aurel Perren, Christoph Stettler, Thomas Krause, Lorenz P. Meier, Renzo Cescato and Martin A. Walter

Journal of Nuclear Medicine November 1, 2016, 57 (11) 1805-1810; DOI: https://doi.org/10.2967/jnumed.115.165092
You have access
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy
Peter Kletting, Thomas Kull, Christian Maaß, Noeen Malik, Markus Luster, Ambros J. Beer and Gerhard Glatting

Journal of Nuclear Medicine April 1, 2016, 57 (4) 503-508; DOI: https://doi.org/10.2967/jnumed.115.164699
You have access
Comparison of the Therapeutic Response to Treatment with a ¹⁷⁷Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
Simone U. Dalm, Julie Nonnekens, Gabriela N. Doeswijk, Erik de Blois, Dik C. van Gent, Mark W. Konijnenberg and Marion de Jong

Journal of Nuclear Medicine February 1, 2016, 57 (2) 260-265; DOI: https://doi.org/10.2967/jnumed.115.167007

Main menu

User menu

Search

PRRT

Pages